Form 4: Ocular Therapeutix Chief Scientific Officer Sells Shares to Cover Tax Obligations

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., sold 3,061 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Jeffrey S. Heier, the Chief Scientific Officer of Ocular Therapeutix, Inc., sold 3,061 shares of the company's common stock on February 24, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on February 22, 2025.
• The shares were sold at a weighted average price of $6.87, with individual transactions ranging from $6.78 to $6.99.
• The sale was conducted under a pre-arranged automatic sale instruction adopted on April 9, 2024, and does not represent a discretionary trade by the reporting person.
• Following the transaction, Heier still beneficially owns 265,998 shares of Ocular Therapeutix common stock.

Sentiment

Score: 6

Explanation: The document describes a routine transaction (sell-to-cover for taxes) by an executive, which is neither particularly positive nor negative. The executive still holds a significant number of shares.

Industry Context

This type of transaction, where executives sell shares to cover tax obligations related to vesting equity, is common in publicly traded companies. It doesn't necessarily reflect a negative outlook on the company's future.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a standard practice across the pharmaceutical and biotech industries.
• Companies like Regeneron, Amgen, and Vertex Pharmaceuticals often see similar transactions by their executives.
• The volume of shares sold is relatively small compared to the total outstanding shares of Ocular Therapeutix, suggesting it's unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price, but is unlikely to significantly affect long-term shareholders.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates